Reword and rewrite the following article in HTML, use a hip journalistic writing style and make the heading statements in H3 or bold font where necessary: If corporations own the seeds of almost everything we eat, why hasn’t anyone managed to do the same thing to cannabis?
Until now, cannabis has lived in a kind of legal and cultural side universe where the usual machinery of seed monopolies never fully clicked into place. That universe is ending. The changes converging around 2026, especially the shift to regulating seeds by THC potential and the slow march toward rescheduling, represent the first plausible structural opening for a Monsanto-style player in weed.
To see what might happen, I have to start with why it hasn’t happened yet.
How Weed Escaped Monsanto While Everything Else Got Captured
The commercial seed market has been growing steadily since the 1990s, driven by deep changes in intellectual property regimes at the core of contemporary capitalism—changes that are hard to fully unpack in a short article. By 2025, the global commercial seed market is already worth north of $80 billion a year and is on track to reach $130–150 billion before the decade is over. While for centuries seeds circulated largely free of modern legal constraints, a large portion of today’s food system now runs on proprietary genetics: patented hybrids in corn and soy, licensed varieties in vegetables, and stacked traits in cotton. Consolidation in the seed sector means that a handful of international firms—such as Bayer (which absorbed Monsanto following its acquisition of the company in 2018), Corteva, Syngenta, and a small supporting cast—control huge portions of the market.
Cannabis, meanwhile, has exploded into its own industrial universe. In the United States alone, regulated adult-use and medical sales were around $31.5 billion in 2025, with forecasts suggesting the national market will approach $40 billion by the end of the decade. Globally, the legal cannabis market is already in the $70 billion range and is projected to more than triple by 2033. That is exactly the kind of growth curve that usually attracts seed giants.
And yet there is still no single company that owns the genetics of cannabis in the way Monsanto once owned Roundup Ready soybeans. There are brands and a few IP-heavy biotech startups, but nothing resembling a true genetic gatekeeper.
Why is that?
The first, most obvious reason is federal illegality. You cannot build a national seed monopoly on a crop that cannot legally move across state lines. For decades, high-THC cannabis has sat in Schedule I. That status has not prevented the U.S. Patent and Trademark Office from issuing large numbers of cannabis-related patents—particularly since 2019—but it has made large-scale genetic consolidation legally and financially risky. At the same time, the groundwork for a future privatization of cannabis genetics has quietly been laid.
A 2025 USPTO patent-mapping analysis by Ruth Fisher, PhD, illustrates this clearly. Out of 8,719 cannabis patents she cleaned and classified, most cluster around therapeutics and delivery systems. But th
